

Table II: Platinum Sensitive: Major Phase III Trials

Study	Trial	RR	PFS/ OS (mos)	Side effects	Comments
ICON 4	Platinum/ Taxane	66%	12/ 29	Myelosuppression; Neuropathy	75% patients with treatment free interval > 12 mos.
	Platinum	54%	9/ 24	Myelosuppression	
OVAR2.5-AGO	Carboplatinum/ Gemcitabine	47%	8.6/ 18	Myelosuppression	60% with treatment free interval of > 12 mos. Was registration trial for Carbo/Gem combination
	Carboplatinum	31%	5.8/ 17	Myelosuppression	
CALYPSO	Carboplatinum/ PLD	NR	11.3/ 31	Myelosuppression	65% with treatment free interval of > 12 mos.
	Carboplatinum/ Paclitaxel	NR	9.4/ 33	Myelosuppression	
OCEANS	Carboplatinum/ Gemcitabine + Bev	79	12.4/ 36*	Myelosuppression; HTN; Proteinuria	59% with treatment free interval of > 12 mos. GI issues not seen with Bevacizumab in this trial
	Carboplatinum/ Gemcitabine	57	8.4/ 30*	Myelosuppression	

NR = Not reported; * = Not mature; GI = Gastrointestinal